GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RCUS · Mar 31, 2026

Arcus Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001724521-26-000034General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

1428.57% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-1971.43% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-12.50% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-1914.29% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1742.86% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

271.43% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History5 statesHistory building

Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20250/7 normalizedLevel 3 Mar 31, 20260/7 normalizedLevel 3 Jun 30, 20265/7 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 300.00%
Current: 1428.57%
Delta: 1128.57%

Capex Intensity Decreased

Previous: 6.06%
Current: 0.00%
Delta: -6.06%

Cash Generation Decreased

Previous: -1460.61%
Current: -1971.43%
Delta: -510.82%

Growth Increased

Previous: -35.29%
Current: -12.50%
Delta: 22.79%

Profitability Decreased

Previous: -1169.70%
Current: -1914.29%
Delta: -744.59%

R And D Intensity Increased

Previous: 1584.85%
Current: 1742.86%
Delta: 158.01%

Sbc Intensity Increased

Previous: 181.82%
Current: 271.43%
Delta: 89.61%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · RCUS Fundamental State →Has State · Arcus Biosciences, Inc. →Transitioned To · RCUS Fundamental State →Transitioned To · RCUS BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · RCUS CAPEX_INTENSITY_DECREASED →Transitioned To · RCUS CASH_GENERATION_DECREASED →Transitioned To · RCUS GROWTH_INCREASED →Transitioned To · RCUS PROFITABILITY_DECREASED →Transitioned To · RCUS R_AND_D_INTENSITY_INCREASED →Transitioned To · RCUS SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.